StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck's (MRK) LYNPARZA Phase 3 SOLO3 Trial Demonstrated 72% OR Rate in Patients with Platinum-Sensitive Relapsed gBRCAm
June 3, 2019 4:19 PM
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada), today presented full results from the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
LYNPARZA® (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patie
June 3, 2019 4:15 PM